莫西沙星在耐多药肺结核治疗中的应用效果探究(1)
[摘要] 目的 探究莫西沙星在耐多药肺结核治疗中的应用效果。方法 方便选取2012年3月—2017年6月期间该院收治的100例耐多药肺结核患者进行分组研究，按照随机数字表法分为对照组(n=50)和治疗组(n=50)，对照组采用左氧氟沙星進行治疗，治疗组采用莫西沙星进行治疗，观察并比较两组临床治疗效果、痰菌转阴率、不良反应情况。结果 对照组的治疗总有效率72.0%显著低于治疗组96.0%，组间差异有统计学意义(P<0.05)；治疗组治疗2、6、12个月的痰菌转阴率44.0%、80.0%、96.0%均明显高于对照组12.0%、48.0%、60.0%，两组差异有统计学意义(P<0.05)；在不良反应发生率比较上，治疗组16.0%低于对照组48.0%(P<0.05)。结论 耐多药肺结核治疗中应用莫西沙星，效果确切，安全可靠，无明显不良反应，值得临床借鉴和进一步普及。
[关键词] 耐多药肺结核；莫西沙星；应用效果
[中图分类号] R521 [文献标识码] A [文章编号] 1674-0742(2018)05(b)-0017-03
[Abstract] Objective This paper tries to investigate the effect of moxifloxacin in the treatment of multidrug-resistant tuberculosis. Methods 100 patients with multi-drug resistant pulmonary tuberculosis treated in this hospital from March 2012 to June 2017 were convenient selected and were divided into a control group (n=50) and a treatment group (n=50) according to the random number table method. The control group was treated with levofloxacin， and the treatment group was treated with moxifloxacin. The clinical treatment effects， the negative rate of sputum conversion and adverse reactions were observed and compared between the two groups. Results The total effective rate in the control group was 72.0%， which was significantly lower than that in the treatment group(96.0%). There was a statistical difference between the two groups (P<0.05). The rate of sputum negative in the treatment group of 2， 6， and 12 months were 44.0%， 80.0%， and 96.0% were significantly higher than those in the control group(12.0%， 48.0%， and 60.0%). There was a statistically significant difference between the two groups(P<0.05). In the incidence of adverse reactions， 16.0% of the treatment group was lower than the control group of 48.0% (P<0.05). Conclusion The use of moxifloxacin in the treatment of multidrug-resistant tuberculosis is effective， safe and reliable， with no obvious adverse reactions， and is worthy of clinical reference and further popularization.
[Key words] Multidrug resistant tuberculosis； Moxifloxacin； Application effect
肺结核属于临床十分常见的肺部感染性疾病之一，而耐多药肺结核则主要指的是患者机体对两种以上抗结核药物(利福平、异烟肼等)耐药的病症，其主要通过呼吸道的途径进行传播，会严重影响患者的身体健康和生命安全。临床研究发现[1]，由于耐多药肺结核患者病程比较长，再加上传染性比较大，治疗难度大，常规抗结核药物治疗方案并不能取得理想的治疗效果。而如何选择科学有效、安全可行的治疗药物或方案是临床亟待解决的问题。该文方便选取2012年3月—2017年6月该院收治的100例耐多药肺结核患者进行分组研究，现报道如下。
1 资料与方法
1.1 一般资料
方便选取该院收治的100例耐多药肺结核患者进行分组研究，纳入标准：①符合《耐药结核病化学治疗指南相关标准》中耐多药肺结核诊断标准[2]；②痰涂片镜检结果呈现阳性，且对两种抗结核药物耐药性明显；③患者治疗依从性良好，通过医院伦理委员会审核批准，自愿签署知情同意书。排除标准：①患有尘肺病、肺外结核、精神障碍、癫痫病等其他病症；②心肝肾功能不全或存在严重障碍；③以往接受过氟喹诺酮类药物治疗。按照随机数字表法分为对照组(n=50)和治疗组(n=50)。对照组：男患者30例(60.0%)，女患者20例(40.0%)，患者年龄在24～70岁之间，平均(38.6±3.5)岁；病程在1～6年之间，平均(2.3±0.4)年；治疗组：男患者28例(56.0%)，女患者22例(44.0%)，患者年龄在25～72岁之间，平均(39.3±3.4)岁；病程在1～7年之间，平均(2.4±0.3)年。对比两组患者基线资料，组间差异无统计学意义(P>0.05)，可进行该次对比。, http://www.100md.com(胡丽华)
[关键词] 耐多药肺结核；莫西沙星；应用效果
[中图分类号] R521 [文献标识码] A [文章编号] 1674-0742(2018)05(b)-0017-03
[Abstract] Objective This paper tries to investigate the effect of moxifloxacin in the treatment of multidrug-resistant tuberculosis. Methods 100 patients with multi-drug resistant pulmonary tuberculosis treated in this hospital from March 2012 to June 2017 were convenient selected and were divided into a control group (n=50) and a treatment group (n=50) according to the random number table method. The control group was treated with levofloxacin， and the treatment group was treated with moxifloxacin. The clinical treatment effects， the negative rate of sputum conversion and adverse reactions were observed and compared between the two groups. Results The total effective rate in the control group was 72.0%， which was significantly lower than that in the treatment group(96.0%). There was a statistical difference between the two groups (P<0.05). The rate of sputum negative in the treatment group of 2， 6， and 12 months were 44.0%， 80.0%， and 96.0% were significantly higher than those in the control group(12.0%， 48.0%， and 60.0%). There was a statistically significant difference between the two groups(P<0.05). In the incidence of adverse reactions， 16.0% of the treatment group was lower than the control group of 48.0% (P<0.05). Conclusion The use of moxifloxacin in the treatment of multidrug-resistant tuberculosis is effective， safe and reliable， with no obvious adverse reactions， and is worthy of clinical reference and further popularization.
[Key words] Multidrug resistant tuberculosis； Moxifloxacin； Application effect
肺结核属于临床十分常见的肺部感染性疾病之一，而耐多药肺结核则主要指的是患者机体对两种以上抗结核药物(利福平、异烟肼等)耐药的病症，其主要通过呼吸道的途径进行传播，会严重影响患者的身体健康和生命安全。临床研究发现[1]，由于耐多药肺结核患者病程比较长，再加上传染性比较大，治疗难度大，常规抗结核药物治疗方案并不能取得理想的治疗效果。而如何选择科学有效、安全可行的治疗药物或方案是临床亟待解决的问题。该文方便选取2012年3月—2017年6月该院收治的100例耐多药肺结核患者进行分组研究，现报道如下。
1 资料与方法
1.1 一般资料
方便选取该院收治的100例耐多药肺结核患者进行分组研究，纳入标准：①符合《耐药结核病化学治疗指南相关标准》中耐多药肺结核诊断标准[2]；②痰涂片镜检结果呈现阳性，且对两种抗结核药物耐药性明显；③患者治疗依从性良好，通过医院伦理委员会审核批准，自愿签署知情同意书。排除标准：①患有尘肺病、肺外结核、精神障碍、癫痫病等其他病症；②心肝肾功能不全或存在严重障碍；③以往接受过氟喹诺酮类药物治疗。按照随机数字表法分为对照组(n=50)和治疗组(n=50)。对照组：男患者30例(60.0%)，女患者20例(40.0%)，患者年龄在24～70岁之间，平均(38.6±3.5)岁；病程在1～6年之间，平均(2.3±0.4)年；治疗组：男患者28例(56.0%)，女患者22例(44.0%)，患者年龄在25～72岁之间，平均(39.3±3.4)岁；病程在1～7年之间，平均(2.4±0.3)年。对比两组患者基线资料，组间差异无统计学意义(P>0.05)，可进行该次对比。, http://www.100md.com(胡丽华)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺结核 > 肺结核